Clinical trial NCT05555342: A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm
Official title: A Novel Method for Treating Lung Metastases With the Combination of Electrical Fields and Radiation Therapy: A Single-Arm Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Lung Tumor
Metastatic Cancer
Keywords: lung metastasis
Stereotactic Ablative Radiotherapy
Percutaneous ablation
irreversible electroporation
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2022-09-26
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.


Eligibility criteria: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed metastatic cancer of any histology. There must be a lung tumor present, although the lung tumor does not specifically need to have been biopsied.
* Patients must have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.
* Patients may have received any number of prior systemic or local therapies. There will be no prespecified washout period prior to IRE. However, systemic therapy will be halted while receiving IRE and radiation, and can be restarted following completion of radiation therapy.
* Up to 3 lesions may be included for treatment. The selected lesion(s) should be amenable to ablation and irradiation and patients will be eligible for ablation and irradiation in the judgment of the treating radiologist and radiation oncologist. If more than one lesion is selected, they should be separated by at least 5 cm to minimize lung irradiation. The target lesion for treatment by IRE and radiation will be a tumor not previously treated by radiation. This target lesion must be measurable, defined as the ability to be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>10 mm with spiral CT scan. The upper limit to the target lesion is 6 cm maximal diameter, but it also must be planned to be encompassed entirely by an IRE ablative zone. Any number of IRE probes will be allowed such that the entire tumor can be ablated.
* Must be age ≥ 18 years. Children are excluded from this study but will be eligible for future pediatric trials, if applicable.

  1. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.
* Performance status: ECOG performance status ≤2 (Karnofsky ≥50%).
* Life expectancy of ≥3 months.
* Adequate organ and marrow function as defined below. Labs should be performed within 14 days of treatment.

  1. Platelets ≥50,000/mcL
  2. Hemoglobin ≥8 g/dL
  3. Absolute neutrophil count ≥1,000/mcL
  4. INR \<1.5
* Female patients of childbearing potential must have a negative urine or serum pregnancy during screening. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* The effects of ionizing radiation (i.e. radiation therapy) on the developing human fetus are known to have the potential for congenital abnormalities and fetal harm. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and until completion of radiation therapy. Should a woman become pregnant or suspect she is pregnant during this period, she should inform her treating physician immediately.

  1. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  1. Has not undergone a hysterectomy or bilateral oophorectomy; or
  2. Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
* Patients must not have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis.
* Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

* Patient's whose target lesion has been previously treated with radiation therapy.
* Patients who have not recovered from adverse events due to prior anti-cancer therapy administered.
* Patients may not be receiving any other investigational agents 2 weeks prior to enrollment and until end of all therapeutic interventions.
* Patients with cardiac arrhythmias, pacemakers, or implanted defibrillator.
* Patients with epilepsy.
* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Patients must not be pregnant due to the potential for congenital abnormalities and fetal harm caused by ionizing radiation.
* Patients with disease amenable to curative intent therapy.
* Patient has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin.

Primary outcomes:
measure: Feasibility, measured as the number of patients completing both IRE and the single fraction of radiation
timeFrame: Up to 3 years
Secondary outcomes:
measure: Number of grade 3-5 adverse events
timeFrame: Up to 3 years
measure: Local failure at the treated site
timeFrame: Up to 3 years
measure: Duration of response
timeFrame: Up to 3 years
measure: Progression-free survival
timeFrame: Up to 3 years
measure: Overall survival
timeFrame: Up to 3 years
measure: Number of grade 1-5 adverse events
timeFrame: Up to 3 years
measure: Patient reported quality of life
timeFrame: Up to 3 years
measure: Forced vital capacity
timeFrame: Up to 3 years
measure: Forced expiratory volume at 1 second (FEV1)
timeFrame: Up to 3 years
measure: Diffusing capacity for carbon monoxide (DLCO)
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Orange
country: United States
facility: Chao Family Comprehensive Cancer Center University of California, Irvine
state: California
Study officials:
affiliation: Chao Family Comprehensive Cancer Center
name: Jeremy Harris, MD
role: PRINCIPAL_INVESTIGATOR
References: